<DOC>
	<DOC>NCT01987843</DOC>
	<brief_summary>The primary objectives of the study are: - To evaluate the safety and tolerability of three dose levels of MT-1303 in subjects with moderate to severe chronic plaque psoriasis. - To evaluate the efficacy of three doses levels of MT-1303 in subjects with moderate to severe chronic plaque psoriasis compared to placebo after 16 weeks of treatment on Psoriasis Area and Severity Index (PASI).</brief_summary>
	<brief_title>Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Have been diagnosed with plaque psoriasis for at least 6 months prior to screening Have moderate to severe chronic plaque psoriasis as defined by PASI score ≥ 12 and BSA ≥ 10% at baseline In the investigator's opinion is a candidate for systemic therapy Nonplaque forms of psoriasis (e.g., guttate, erythrodermic or pustular) Current druginduced or aggravated psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from betablockers, calciumchannel blockers, or lithium carbonate) History of any of a list of predefined cardiovascular diseases History or known presence of any significant infectious, metabolic, oncological, ophthalmological or respiratory system disease or illness likely to render the subject unsuitable for the study. Previous exposure to any other S1P receptor modulator Receipt of a live vaccine within 28 days prior to randomisation Need, or likely need for, treatment with Class I or III antiarrhythmic drugs or with heartratelowering betablockers or calciumchannel blockers, or with any other drugs which can reduce the heart rate Clinically significant findings electrocardiogram (ECG) findings.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Plaque Psoriasis</keyword>
</DOC>